BioSpace News Archive

Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to release the CEO’s letter to the shareholders.

Grey Cloak Tech Inc. (OTC: GRCK – name change pending to Healthy Extracts Inc.), today announces that its BergaMet NA subsidiary has introduced BergaMet Clinical IMMUNE™, a concentrated nutraceutical supplement formulated with naturally grown, heart-healthy Citrus Bergamot SuperFruit™, BetaVia™ Complete, and nine other powerful immune-boosting ingredients to create the No. 1 immune system defense for the body.

Patent Broadens Core Intellectual Property for the Intratumoral Delivery of Stimulatory Interleukins Using OncoSec’s Proprietary Electroporation (EP) Technology Platform

Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of Franz B. Humer, Ph.D., as Executive Chairman of the Board of Directors. A world-renowned pharmaceutical industry trailblazer, Dr. Humer ser

Mesuron Inc. is a US commercial company specializing in the development and fabrication of SQUID-based magnetometers for various applications

Atrility Medical today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the AtriAmp™ Device. The AtriAmp facilitates more efficient monitoring and treatment of atrial arrhythmias, a common side-effect of many heart surgeries.

The pursuit of an effective therapeutic intervention for dementia has inspired interest in the class of medications known as tyrosine kinase inhibitors (TKIs)

International research firm Parks Associates will feature new consumer research and insights from industry leaders representing ANGI Homeservices/Handy, Everise, Infineon Technologies, Sutherland, and Sweepr at the CONNECTIONS™ Community virtual event Support: Onboarding and Ongoing Services, Wednesday, October 7, 11 a.m. CT.

Tarsus Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company, announced data from its Phase 2 trials, Io (a Phase 2a, single-arm open-label trial) and Europa (a Phase 2b, randomized vehicle-controlled trial), evaluating the safety and efficacy of TP-03, a novel ophthalmic therapeutic being developed for the treatment of Demodex blepharitis

RAD Women (#RADxx), a networking and mentorship group for women in radiology, informatics, and IT management of radiology systems has announced that nominations for the 4th annual RADxx Awards are now open.